Synthesis of a-L-Threofuranosyl Nucleoside Triphosphates
Keyong Zou,1 Allen Horhota,3 Biao Yu,2 Jack W. Szostak,1 Larry W.
1Howard Hughes Medical Institute, and Department of Molecular Biology,
Massachusetts General Hospital, Boston, Massachusetts 02184, and 2State Key
Laboratory of Bio-organic and Natural Products Chemistry, Shanghai Institute of Organic
Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai, 200032, China,
and 3Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut
General Information
Chemicals and reagents were purchased from Sigma/Aldrich unless otherwise noted.
Pyridine and tributylamine were distilled from calcium hydride, DMF from phosphorus
pentoxide, and dioxane was dried over sodium. TNA triphosphate syntheses were carried
out according to a modified version of the methods developed by Ludwig and Eckstein.1
Advanced intermediates 1 of thymine, 2,6-diaminopurine, and guanine threofuranosyl
nucleosides with 2'-O-DMT and heterocyclic protecting groups were a generous gift of
the Eschenmoser laboratory. The protecting groups for the heterocyclic 2,6-
diaminopurine and guanine bases were removed prior to phosphorylation, but the 2'-O-
DMT protecting group remained in place. Compound 4 was prepared from L-ascorbic
acid and N4-benzoyl cytosine as reported.2 Phosphorylation reactions were monitored by
TLC on EMD 60 F253 silica plates run in 1-propanol/NH4OH/H2O (11:7:2) visualized
under UV light. Ion exchange chromatography was performed using DEAE Sephadex
(Pharmacia) in a Waters 600 HPLC with UV detection eluting with 0-1 M TEAB pH 7.5
followed by reverse phase HPLC purification on a divinyl benzene column eluting with
95% 100 mM TEAA pH 7.0 and a linear gradient from 5% methanol to 100% methanol.
The sodium salt was prepared according to the method described by Hoard and Ott.3
(a-L-Threofuranosyl)thymine-3'-triphosphate, (a-L-threofuranosyl)-2,6- diaminopurine-3'-triphosphate, and (a-L-threofuranosyl)guanine-3'-triphosphate (tTTP, tDTP and tGTP, 3)
2'-O-DMT protected threosyl nucleosides were co-evaporated twice from dry pyridine
and stored under high vacuum over P2O5. for 1 hr. The nucleosides were dissolved in
appropriate solvents and reacted with 2-chlor-4H-1,3,2-benzodiozaphosphorin-4-one in
dry dioxane (1 M stock, 1 mol eq.) After 10 minutes tributylammonium pyrophosphate
solution in dry DMF (0.5 M stock, 1.5 mol. eq.) and tributylamine (1/3 vol. of
pyrophosphate solution) were added and the reaction was allowed to stir for 15 min. I2
solution in pyridine/Water (98:2) (1% stock, 1 mol. eq.) was added to the reaction
mixture with 5% sodium sulfite solution (~ 1/3 volume of I2 solution) was added after 10
minutes to quench excess iodine. Solvents were removed under high vacuum. The residue
was dissolved in 50% acetic acid for 20 min at 0 oC followed by solvent removal. The
residue was then dissolved in water (5 ml) and washed twice with diethyl ether. Ion
exchange and reversed-phase HPLC purification followed by conversion to the sodium
salts resulted in the threosyl nucleoside 3'-triphosphates in 25-35% yields. (a-L-Threofuranosyl)thymine-3'-triphosphate
1-{2'-O-[(4',4''-dimethoxytriphenyl)methyl]-a-L-threofuranosyl}thymine (10 mg, 19
mmol) was dissolved in 20 ml pyridine and 60 ml dioxane for the phosphorylation reaction
performed as described above. Yield 35%. 31P NMR (161.9 MHz, D2O) d -8.35 (d,
Jp,p=19 Hz), -10.60 (d, Jp,p=19 Hz), -21.99 (t, Jp,p=19 Hz). UV (20 mM Tris-HCl pH 7.5)
(a-L-Threofuranosyl)-2,6-diaminopurine-3'-triphosphate N2,N6-Dibenzoyl-9-{2'-O-[(4', 4''-dimetheoxytriphenyl)methyl]-a-L-threofuranosyl}-2,6-
diaminopurine was deprotected in 8 M methylamine in ethanol:12 M methylamine in
water (1:1) for 3 hr at 50 oC followed by solvent removal and silica gel flash
chromatography (0 to 4% methanol in CH2Cl2) yielding 9-{2'-O -[(4', 4''-
dimethoxytriphenyl)methyl]-a-L-threofuranosyl}-2,6-diaminopurine in near quantitative
yield as confirmed by LRMS. This material (10 mg, 18 mmol) was dissolved in 30 ml
pyridine and 120 ml DMF for the phosphorylation reaction. Yield 25%. 31P NMR (202.4
MHz, D2O) d -6.84 (d, Jp,p= 18 Hz), -11.73 (d, Jp,p= 18 Hz), -19.95 (t, Jp,p= 14 Hz). ESI-
MS (neg.) 490.9883 (HRMS calc. 490.9886 ). UV (20 mM Tris-HCl pH 7.5) lmax 282
(a-L-Threofuranosyl)guanine-3'-triphosphate N2-Acetyl-O6-diphenylcarbamoyl)-9-{2'-O-[(4',4''-dimetheoxytriphenyl)methyl]-a-L-
threofuranosyl}guanine was deprotected in 8 M methylamine in ethanol:12 M
methylamine in water (1:1) for 3 hr at 50 oC followed by solvent removal and silica gel
flash chromatography (0 to 4% methanol in CH2Cl2) yielding 9-{2'-O-[(4',4''-
dimethoxytriphenyl)methyl]-a-L-threofuranosyl}guanine confirmed by LRMS. This
material (10 mg, 18 mmol) was dissolved in 30 ml pyridine and 120 ml DMF for the
phosphorylation reaction. Yield 25%. 31P NMR (161.9 MHz, D2O) d -3.08 (d, Jp,p= 18
Hz), -10.40 (d, Jp,p= 18 Hz), -19.07 (t, Jp,p= 18 Hz). UV (20 mM Tris-HCl pH 7.5) lmax
N4-Benzoyl-1-{2'-O-acetyl-3'-O-[(4', 4''-dimetheoxytriphenyl)methyl]-a-L- threofuranosyl}cytosine (5) N4-Benzoyl-1-{3'-O-[(4',4''-dimetheoxytriphenyl)methyl]-a-L-threofuranosyl}cytosine
(4, 1 g, 1.62 mmol), prepared starting from L-ascorboc acid and N4-benzoyl cytosine as
described,2 was co-evaporated twice from dry pyridine (30 ml). Acetic anhydride (275
ml, 2.92 mmol) was added to the solution of 4 in dry pyridine (30 ml). The mixture was
stirred under argon at room temperature for 12 hrs, and then evaporated to dryness after
MeOH (2 ml) was added to quench the reaction. The residue was dissolved in CH2Cl2
and washed with sat. aq. NaHCO3 solution, H2O and sat. aq. NaCl solution, dried
(Na2SO4) and filtered. The residue after evaporation was purified by silica gel flash
chromatography [hexane/CH2Cl2/TEA (1:1:0.0025) to CH2Cl2 /TEA(1:0.0025)] to give 5
TLC (4% MeOH in CH2Cl2): Rf 0.32. 1H-NMR (400 MHz; CDCl3) d 8.82 (bs, 1H), 7.96
(m, 3H), 7.20-7.63 (m, 13H), 6.79-6.84 (m, 4H), 5.93 (bs, 1H), 5.53 (bs, 1H), 4.24 (m,
1H), 3.76-3.78 (2s, 6H), 3.60 (dd, J=14.8, J=7.2, 1H), 3.05 (dd, J=14.8, J=7.6, 1H), 2.08
(s, 3H). 13C NMR (100 MHz; CDCl3) d 168.7, 162.5, 159.0, 145.4, 144.3, 135.8, 135.3,
133.3, 130.1, 130.0, 129.2, 128.3, 128.1, 127.7, 127.5, 113.8, 113.7, 96.6, 91.4, 88.9,
81.3, 76.4, 75.1, 55.6, 21.2 (hexane residues: 31.6, 22.7, 14.1). ESI-MS (pos.) 684.2324
N4-Benzoyl-1-(2'-O-acetyl-a-L-threofuranosyl)cytosine (6) N4-Benzoyl-1-{2'-O-acetyl-3'-O-[(4',4''-dimetheoxytriphenyl)methyl]-a-L-
threofuranosyl}cytosine (5, 500 mg, 0.76 mmol) was treated with 3% TCA in CH2Cl2 (25
ml) at ambient temperature for 3 min. MeOH was added dropwise to quench released
DMT cation until the orange color disappeared. After the acid was neutralized by
triethylamine (~10 ml), the mixture was immediately evaporated to avoid deacylation by
overexposure to the basic solvent in the presence of MeOH. The residue was purified by
silica gel flash chromatography (2% MeOH in CH2Cl2). There was still ~ 12% of 5
(tritylated nucleoside) that was subjected to another TCA treatment and column
purification. Product fractions were combined to afford 6 (251 mg, 92%) as a white foam.
TLC (4% MeOH in CH2Cl2): Rf 0.23. 1H NMR (400 MHz; DMSO-d6) d 11.26 (bs, 1H),
8.14 (d, J=6.4, 1H), 8.02-7.50 (m, 5H), 7.36 (d, J=6.4, 1H), 5.81 (bs, 1H), 5.72 (bs d,1H),
5.12 (bs, 1H), 4.76 (d, J=9.347, 1H), 4.17 (m, 2H), 2.11 (s, 3H). 13C NMR (100 MHz;
DMSO-d6) d 169.7, 168.0, 164.0, 155.0, 146.1, 133.9, 133.3, 129.1, 129.0, 96.4, 91.5,
81.7, 77.2, 73.1, 21.5. ESI-MS (pos.) 382.1015 [M+Na]+ (HSMS calc. 382.1015). (a-L-Threofuranosyl)cytosine-3'-triphosphate (tCTP, 8) N4-Benzoyl-1-(2'-O-acetyl-a-L-threofuranosyl)cytosine (6 , 10 mg, 28 m mol) was
dissolved 30 ml dry pyridine and 90 ml dry dioxane for the phosphorylation reaction. The
reaction was carried out as described above except for the treatment with acetic acid.
After the excess of iodine was quenched and the solvent was removed under high
vacuum, the residue was treated with ammonium hydroxide (28%, 10 ml) at ambient
temperature for 3 hours before evaporating to dryness. The residue was dissolved in
water (5 ml) and washed twice with CH2Cl2. Ion exchange and reverse phase HPLC
purification gave 8 in 30% yield.
31P NMR (161.9 MHz, D2O) d -3.78 (d, Jp,p = 18 Hz), -11.33 (d, Jp,p = 18 Hz), -18.87 (t,
Jp,p = 18 Hz). ESI-MS (neg.) [M-H]- 452.0. UV (20 mM Tris-HCl pH 7.5) lmax 271 nm. References for supporting information:
(1) Ludwig, J.; Eckstein, F. J. Org. Chem.1989, 54, 631-635.
(2) Schöning, K.-U., Scholz, P.; Wu X.; Guntha, S.; Delgado, G.; Krishnamurthy, R.;
Eschenmoser, A. Helvetica Chimica Acta2002, 85, 4111-4153.
(3) Hoard, D. E.; Ott, D. G. J. Am. Chem. Soc.1965, 87, 1785-1788.
Social Science & Medicine 69 (2009) 14–20The promotion of olanzapine in primary care: An examination of internal industrydocumentsDepartment of Psychology, Metropolitan State University, 1450 Energy Park Drive, St. Paul, MN 55108, United StatesMedia reports have discussed how olanzapine was marketed off-label for dementia and subsyndromalbipolar disorder. Much of this marketing occur
For Broker/Dealer use only. Not for distribution to the public. x Face Amount Age 16-391 Age 40-49 Age 50-60 IMPORTANT INFORMATION Less than $100,000 amount of all Phoenixpolicies issued in the past 12 months plus any risk $100,000 to $250,000 $250,001 to $500,000 $500,001 to $1,000,000 by one of our approvedexamination servicecompanies. $1,000,001 to